A comprehensive view of Neurological/Cognitive Health. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

In the migraine treatment drug market, Q2 sales of Lilly’s Emgality hit US$157.5M, AbbVies’s Ubrelvy sales total US$138.0M, Biohaven’s Nurtec has US$123.6M in sales; Amgen’s Aimovig records US$92.0M in sales in Q2

Biogen’s staff count at Cambridge, Massachusetts, site drops by 301 employees since first of the year reports Boston Business Journal; Biogen to lay off as many as 1,000 employees in US$1B cost-cutting plan due to failure of Aduhelm Alzheimer’s drug

FDA starts priority review of Eli Lilly’s donanemab injectable Alzheimer drug designed to clear amyloid plaque from brain; late-stage study results expected by middle of 2023

Boston Scientific to pay Nevro Corp. US$85.0M to settle intellectual property litigation; Boston Scientific and Nevro free to continue using features, capabilities embodied in their current spinal cord stimulation technology products

KU Medical Center to study if wearable device can decrease disability after stroke; clinical trial to learn if frequency-tuned electromagnetic energy from device that fits over the head, torso can stimulate brain, spinal cord to decrease disability

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count